T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms, drug landscape, and clinical applications with no systematic review or primary data
PubMed 38672662 · doi:10.3390/cancers16081580
What was done
This narrative review summarizes the structural and functional principles of T-cell engagers (TCEs)—bispecific antibodies that simultaneously bind tumor-associated antigens and CD3 on T-cells—and outlines their clinical use in hematological malignancies including acute lymphoblastic leukemia, acute myeloid leukemia, multiple myeloma, and lymphomas.
What was found
The abstract reports regulatory and clinical milestones rather than numerical efficacy metrics. Following the 2014 FDA approval of blinatumomab for acute lymphoblastic leukemia, seven TCE therapies gained market approval by November 2023 across several hematologic cancers.
Why it matters
T-cell engagers harness endogenous T-cell cytotoxicity against tumor cells without requiring ex vivo cellular manipulation, representing a major class of targeted immunotherapy for hematological malignancies.
Limits
As a narrative review, the paper presents no primary clinical data, systematic search criteria, or quantitative outcome metrics (such as response rates, progression-free survival, or adverse effect rates). Abstract provides no numerical performance data.
Cited by
- supports Bispecific T-cell engagers (BiTEs) are dual-binding antibodies designed to simultaneously bind a target on a cancer cell and a target on a T cell, directing endogenous T cells to kill the cancer cell without requiring genetic modification of the T cells.